Certara, a leading provider of decision support technology and consulting services for optimising drug development and improving health outcomes, has announced it has acquired d3 Medicine.
d3 Medicine, based in the US and Australia, provides strategic planning and stewardship of complex drug development programs. The company's d3 staff will become part of Certara’s Strategic Consulting (CSC) division, which was formed in July 2015 through the merger of Quantitative Solutions and Pharsight Consulting Services.
CSC is the largest consultancy of its kind; it now has more than 100 scientists, the majority with PhDs, using a broad range of modeling and simulation methods and technologies to support global sponsors in bringing new therapies to patients.
“d3 Medicine’s addition to Certara continues to strengthen our ability to provide our clients with optimised and strategic drug development plans that leverage our unique modeling and simulation, and regulatory advisory and communications expertise,” said Certara CEO Dr Edmundo Muniz.
“Our shared mission is to revolutionise the drug development paradigm by applying quantitative science and technologies in an integrated manner to inform the most crucial drug development decisions. To that end, Certara has helped sponsors bring more than 80 new drugs to market, including more than 40 percent of the novel drugs approved by the US Food and Drug Administration last year.”
The company said the addition of d3 Medicine provides Certara with expanded capabilities and expertise, most notably in the areas of oncology, orphan diseases, infectious diseases and inflammation, including:
- drug development optimisation strategy, stewardship and implementation;
- regulatory consulting and liaison services with global health authorities; and,
- pressure testing and optimising licensing and M&A plans.
“We are thrilled to be joining Certara, the most innovative and seasoned modelling and simulation drug development company in the world,” said Dr Craig Rayner, CEO of d3 Medicine.
“We share a commitment for putting the patient first and thinking differently, which enables us to accelerate development and optimise the use of new medicines.”
“Regulatory strategy, drug development, and clinical pharmacology reflect the core interests of the top R&D economic decision makers in the pharmaceutical industry. As clinical pharmacology comprises more than 50 percent of a drug label, the need to understand how to optimise safety and efficacy in all patients is critical. This ‘sweet spot’ of drug development is where d3 and Certara live,” added Dr Rayner.